Two spacer devices for aerosol inhalation were compared by a crossover study of FEV 1 response to 200 μg of salbutamol in 20 asthmatics evaluated in separate days. Fisonair ® (750 ml reservoir) use led to an average 0.32 L increase in FEV 1, which was significantly higher than the 0.26 L obtained with Jet® (103 ml reservoir) (p = 0.02). Bronchodilator response with Jet® was 21% lower (CI: -7 to -35%) than with Fisonair ® .

Keywords: Asthma. Aerosols. Delivery systems.

Objective: To evaluate the capacity of the criteria described in Complementary Directive SAS/MS 12, issued on November 12, 2002, to identify patients with severe asthma, describing and comparing clinical, functional and treatment data of such patients. Methods: This was a nested case-control study using a structured database for adult asthma outpatients. We defined cases as asthma patients who met the inclusion criteria described in the directive, defining controls as those who did not. We collected and compared data related to the following: demographic characteristics; history of asthma; medications in use; comorbidities; history of tobacco use; number of exacerbations within the last 12 months, asthma-related hospitalizations and intensive care unit admissions within the last 12 months; spirometry; and sputum cytology. Results: The case and control groups consisted of 29 and 31 patients, respectively. The number of asthma exacerbations and emergency room visits within the last 12 months, as well as the number of patients that received at least one pulse of oral corticosteroids, was significantly higher in the case group than in the control group. In addition, prebronchodilator FVC was lower among the cases than among the controls. Furthermore, cytology revealed that eosinophil counts were significantly higher in the induced sputum of cases than in that of controls. Conclusions: The criteria described in the directive are suited to stratifying patients with severe asthma.

Keywords: Asthma; Budesonide; Combined modality therapy.